Want to join the conversation?
$BAX 2Q15 Call: Performance in the quarter was driven by mid to high single digit growth in our peritoneal dialysis business and double digit growth in the acute business. This growth was offset by lower sales in our chronic hemodialysis business, resulting from our previously mentioned decision to forgo certain lower margin sales opportunities.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.